Routine annual meeting results with no earnings or operational data. The 400,000-share increase under the incentive plan and 190,000-share increase under the ESPP are standard compensation authorizations. Monitor the next quarterly filing for any impact from equity grants on share count.
Price Chart
Executive Summary
Harvard Bioscience held its 2026 Annual Meeting on June 2, 2026, where stockholders approved an amendment to the Employee Stock Purchase Plan (increasing authorized shares by 190,000) and the Amended and Restated 2021 Incentive Plan (increasing authorized shares by 400,000). Two Class II directors were elected, and Grant Thornton LLP was ratified as the independent auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved an amendment to the Employee Stock Purchase Plan, increasing authorized shares by 190,000.
- Stockholders approved the Amended and Restated 2021 Incentive Plan, increasing authorized shares by 400,000.
- John Duke and Katherine A. Eade were elected as Class II directors for three-year terms.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for FY2026.
- The non-binding advisory vote on named executive officer compensation passed with 1,768,695 votes for and 57,111 against.
- The Amended and Restated 2021 Incentive Plan passed with 1,131,261 votes for and 680,030 against, indicating notable opposition.
Financial Impact
No financial figures reported. The share increases under the equity plans represent potential future dilution but no immediate cash impact.
Risk Factors
- Potential dilution from future equity awards under the incentive plan and ESPP.
- The 680,030 votes against the incentive plan (37.5% of votes cast excluding broker non-votes) suggests notable shareholder dissent.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003877 |
| Exhibit: exh_102.htm | 0001171843-26-003877 |
| Document: 0001171843-26-003877-index-headers.html | 0001171843-26-003877 |
| Document: 0001171843-26-003877-index.html | 0001171843-26-003877 |
| Document: 0001171843-26-003877.txt | 0001171843-26-003877 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | SC 13G/A | $7.92 | awaiting T+60 | — | $8.32 (+5.05%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Aug 11, 2026 10w ago | 8-K | $6.13 | awaiting T+60 | — | $8.32 (+35.73%) |
Jul 28, 2026 12w ago | Press Release | $5.92 | awaiting T+60 | — | $8.32 (+40.54%) |
Jun 2, 2026 20w ago | 8-K | $6.50 $7.90 | ▲ +21.54% | ▲ +19.04% | $8.32 (+28.00%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
May 12, 2026 23w ago | 8-K | $5.41 $6.19 | ▼ −14.42% | ▼ −10.03% | $8.32 (−53.79%) |
May 12, 2026 23w ago | Press Release | $5.41 $6.19 | ▲ +14.42% | ▲ +10.03% | $8.32 (+53.79%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
Mar 16, 2026 32w ago | Insider Cluster | $5.01 $6.01 | ▲ +19.96% | ▲ +9.48% | $8.32 (+66.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers